Immunome, Inc.

Healthcare · Biotechnology · United States

Last price 18.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.07B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including I...